



MELANOMA AND MELANOCYTIC NAEVI

VITILIGO-LIKE DEPIGMENTATION IN ADVANCED MELANOMA UNDER BRAFI-MEKI TARGET THERAPY: AN UPDATE

Susanna Gunnella⁽¹⁾ - Sara Fortunato⁽²⁾ - Mariasimona Pino⁽³⁾ - Serena Sestini⁽⁴⁾ - Carlotta Ottanelli⁽³⁾ - Sheila Rangan⁽³⁾ - Lorenzo Borgognoni⁽⁴⁾ - Luisa Fioretto⁽³⁾ - Nicola Pimpinelli⁽⁵⁾

Ospedale Santa Maria Annunziata, Dermatologia, Firenze, Italy⁽¹⁾ - Ospedale Santa Maria Annunziata, Dermatologia, Firenze, Italy⁽²⁾ - Ospedale Santa Maria Annunziata, Oncologia, Firenze, Italy⁽³⁾ - Ospedale Santa Maria Annunziata, Chirurgia Plastica, Firenze, Italy⁽⁴⁾ - Ospedale Santa Maria Annunziata, Dermatologia, Firenze, Italy⁽⁵⁾

Background: Vitiligo like reaction is a relatively common cutaneous side effect in patients with metastatic melanoma during treatment with immunotherapy (anti-CTLA4 and anti-PD1). Although recent studies suggest that BRAFi/MEKi targeted therapies also induce an immune response against melanoma, via multiple mechanisms involving the immune microenvironment.

Observation: We report our cases of vitiligo-like reaction in stage IV melanoma treated with BRAFi-MEKi target therapy.

A case of vitiligo like reaction in ECT-treated area for cutaneous secondarism of melanoma during BRAFi-MEKi systemic target therapy, and two cases of face depigmentation appeared spontaneously after 24 months from the beginning of BRAFi-MEKi target therapy during stable and good response to BRAFi-MEKi target therapy.

Key message: There are no cases of vitiligo-like reaction during BRAFi-MEKi target therapy reported to date.

The destruction of melanocytes in depigmented skin areas may represent an enhanced immune response to melanoma.

We report these cases for the correlation of the development of these vitiligo-like reaction during a good response to the BRAFi-MEKi target therapy, like as these skin reaction could represent a positive prognostic factor.

